Compare AbCellera Biologics Inc (ABCL) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Alliant Energy Corporation — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Alliant Energy Corporation trades at $76.42 (market cap $20.06B). The key difference: Alliant Energy Corporation is far larger — about 8.5× AbCellera Biologics Inc's market cap, and Alliant Energy Corporation pays a 2.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LNT | |
|---|---|---|
Market Cap | $2.35B | $20.06B |
Sector | Health | Utilities |
52-Week High | $8.12 | $78.03 |
52-Week Low | $2.78 | $61.26 |
Enterprise Value | $1.99B | $31.78B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LNT trades at $77.65, down 0.49% on the day, with a bullish technical signal from moving averages and key resistance at $78. The company reported revenue of $4.36B in 2025 with net income of $810M, and recent quarters show mixed earnings performance against estimates. A $13.4B investment plan supports growth in data center demand and clean energy expansion, while analyst consensus is a Buy with a $75.67 price target.
LNT offers steady utility earnings growth and a dividend yield, but faces risks from rising debt levels and interest expenses. The stock's valuation multiples are above sector averages, requiring continued execution on capital investments to justify premium pricing amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
